More ADHD Medication Isn’t Always Better
Researchers mapped optimal ADHD drug doses to maximize benefits while minimizing side effects.
Prescribing the right dosage of medication for attention-deficit/hyperactivity disorder (ADHD) often comes down to a game of trial and error for both doctors and those affected.
However, a new study, led by researchers at the University of Southampton and the University of Lyon, has mapped precise dose-effect curves for many commonly prescribed ADHD drugs.
The results revealed where treatment benefits peak and the dosages where the side effects outweighed their benefit.
Understanding the challenges of dosing ADHD medication
ADHD affects ~7%–10% of school-age children globally and 2%–5% of adults. Medication is often the first pillar in managing the condition, with prescription rates rising significantly in recent years. However, determining the correct dosage remains a distinct challenge for doctors and families.
If a dose is too low, patients can miss out on clinical benefits, known as subtherapeutic prescribing. This is common in children and adolescents, leading to poor treatment adherence as patients feel the medicine does not work. On the other hand, prescribing too high a dose leads to unnecessary side effects.
Most current clinical guidelines offer minimal assistance on precise dosing strategies. Four previous meta-analyses investigated dose effects; however, they only compared individual medications directly against placebos—failing to evaluate multiple treatments simultaneously across different age groups.
An international research team conducted the first comprehensive network meta-analysis of oral ADHD treatments. The project mapped clear dose-effect curves for both effectiveness and side effects across children, adolescents, and adults. The researchers also evaluated what happens when prescriptions exceed standard licensed maximum limits.
Key data and clinical findings on ADHD drug efficacy
The team used the MED-ADHD database to analyze 113 double-blind randomized controlled trials, comprising over 25,000 participants, split into 68 studies focused on children or adolescents and 45 studies on adults. The researchers tracked treatment effectiveness via symptom reduction scales alongside patient dropouts caused by adverse side effects.
ADHD medication guide
- Stimulants: The most common type of medication prescribed for ADHD that include methylphenidate and amphetamines.
- Non-stimulants: Alternative options that include atomoxetine, extended-release guanfacine, modafinil, and viloxazine.
The results revealed distinct ADHD medication patterns across different age groups.
In children and adolescents, the benefits of methylphenidate peaked at ~45 mg/day, with higher doses showing no added group benefit. Amphetamines and guanfacine peaked at ~25 mg/day and ~4 mg/day, respectively. Pushing past these points did not help patients; instead, it triggered clear, dose-dependent increases in dropouts due to side effects. No clear dosing patterns emerged for atomoxetine or modafinil.
For adults, amphetamines reached a clear effectiveness plateau above 50 mg/day, while the risk of stopping treatment due to side effects rose steadily above this line. Adult symptom reduction for methylphenidate trended upward without a distinct plateau, which the team attributed to sparse high-dose data. However, patient tolerability dropped significantly once adult doses exceeded 50 mg/day.
By tracking the initial upward curve of effectiveness, the data validated concerns around subtherapeutic prescribing, demonstrating that keeping doses below the identified peaks deprives patients of necessary symptom control without offering safety benefits.
Clinical implications and new tools for ADHD management
“Overall, our findings suggest that clinicians should avoid using doses that are too low to be effective. If symptoms are not well controlled, the dosage may need to be increased,” said first author Dr. Mikail Nourredine from the University of Lyon.
Building Confidence for Regulatory Decision Making With Immune-Competent Live Models
This webinar explores how liver microphysiological systems (MPS) are being benchmarked through cross-platform studies, including work accepted into the FDA iSTAND program, to build regulatory confidence in drug-induced liver injury (DILI) assessment.View Webinar
However, pushing past guidelines rarely helped the average patient.
“We also found no evidence that going beyond the licensed maximum doses improves average effectiveness, and higher doses are usually linked to more side effects. However, our results derive from group averages. Specific individuals with ADHD may benefit from and tolerate well unlicensed doses,” Nourredine added.
To turn this data into practical clinical care, the team launched a free online interactive tool.
“Our study and the tool have the potential to support shared decision-making between clinicians, patients, and families when choosing the best dose. It is not only a clinician’s decision—patients and caregivers should be involved,” said Prof. Samuele Cortese, an NIHR research professor at the University of Southampton.
“The tool helps show what can be expected from each dose so that the patient knows why that particular dose has been chosen. We are continuing research to further personalize these recommendations based on individual patient characteristics,” they added.
Reference: Nourredine M, Jurek L, Hamza T, et al. Pharmacological interventions for ADHD: a systematic review and dose–effect network meta-analysis. The Lancet Psychiatry. 2026;13(6):485-495. doi: 10.1016/S2215-0366(26)00091-X
This article is a rework of a press release issued by the University of Southampton. Material has been edited for length and content.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
